false
0001971532
0001971532
2025-07-23
2025-07-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 23, 2025
TELOMIR
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
| Florida |
|
001-41952 |
|
87-2606031 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification No.) |
100
SE 2nd St, Suite 2000, #1009
Miami,
Florida
(Address of Principal Executive Offices)
Registrant’s
telephone number, including area code: (786) 396-6723
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| |
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
| |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, no par value |
|
TELO |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events
Telomir
Pharmaceuticals Reports Telomir-1 Demonstrates a Rare Mitochondrial Activity Profile by Selectively Restoring Energy and Improving Oxidative
Balance in Diseased Human Cell Lines Without Causing Them to Divide
Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO) today reported new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial
function without triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria
Syndrome (HGPS).
The
study was conducted in collaboration with Smart Assays Biotechnologies Ltd., a preclinical contract research organization specializing
in advanced cell-based models and drug mechanism profiling. Researchers used a Progeria human fibroblast cell line to evaluate Telomir-1’s
effects on mitochondrial energy production, oxidative balance, and cell replication.
Telomir-1
demonstrated a rare mitochondrial activity profile by selectively increasing mitochondrial energy production while simultaneously reducing
reactive oxygen species (ROS)—a damaging byproduct of oxidative metabolism. Notably, this restoration occurred without causing
the cells to divide, a key safety consideration in genetically unstable or disease-compromised cells.
This
combination—enhanced mitochondrial function, reduced oxidative stress, and no induced proliferation—sets Telomir-1
apart from many mitochondrial-targeted compounds. Typically, agents that increase mitochondrial energy also raise ROS levels, which can
further damage fragile tissues. Telomir-1’s ability to restore energy while improving oxidative balance and avoiding cell proliferation
suggests a differentiated therapeutic profile.
Key
findings from the study include:
| ● | Increased
mitochondrial energy production, as measured by WST-1 assay, indicating improved energy
metabolism in compromised cells |
| ● | Reduced
ROS levels, under both basal and iron- or copper-induced stress conditions |
| ● | No
increase in live cell number, as measured by Calcein assay, confirming no stimulation
of cell proliferation |
| ● | Stronger
activity in Progeria cells than in healthy fibroblasts, suggesting disease-selective
effects |
The
observed profile may be relevant to other diseases where mitochondrial failure, oxidative stress, and limited regenerative capacity contribute
to progression, including Parkinson’s disease, ALS (Amyotrophic Lateral Sclerosis), Alzheimer’s disease, Werner’s
syndrome, and Progeria.
Telomir
is completing IND-enabling studies for Telomir-1 and continues to evaluate multiple clinical development paths based on scientific rationale,
unmet need, and regulatory strategy.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
TELOMIR
PHARMACEUTICALS, INC. |
| |
|
| Dated:
July 23, 2025 |
By: |
/s/
Erez Aminov |
| |
Name:
|
Erez
Aminov |
| |
Title: |
Chief
Executive Officer |
